Skip to main content
. Author manuscript; available in PMC: 2018 May 15.
Published in final edited form as: Am J Cardiol. 2017 Mar 22;119(10):1637–1642. doi: 10.1016/j.amjcard.2017.02.008

Figure 2. Individuals that experience cancer therapeutics-related cardiac dysfunction (CTRCD) defined as LVEF drops of >10% or a decline to an absolute value of <50%, 3 months after initiating potentially cardiotoxic chemotherapy.

Figure 2

Participants who experienced CTRCD due to isolated LVEDV declines are shown in the white box; those who experience increases in LVESV with minimal changes to LVEDV (impaired LV contractility) are shown in the black box; participants who had a combination of LVEDV drop and LVESV increase are shown in white and black box and those with minor LVEDV and LVESV changes are shown in the gray box.